Prescribing Lurasidone

At a glance

The metabolically clean antipsychotic for bipolar depression that also treats schizophrenia; it only works with a meal, and akathisia is the cost.

How to doseFull section

Comes as

Tablet20, 40, 60, 80, 120 mg

Example photos; looks vary by maker. Click to enlarge.

In shortStart schizophrenia at 40 mg and bipolar depression at 20 mg once daily, with food of at least 350 calories; label maximums are 160 mg and 120 mg a day.

FDA labelIn practice

A row across both columns means the label and usual practice agree. Off-label marks the few places where practice goes beyond what the label allows.

Adultsschizophrenia; bipolar depression

SchizophreniaFDA labelStart 40 mg once daily. Shown effective from 40 to 160 mg per day. Maximum 160 mg per day. No initial titration needed.In practiceStart 40 mg once daily with food. 80 mg is a common effective dose. 160 mg outperforms lower doses for refractory positive symptoms.

Bipolar depressionFDA labelStart 20 mg once daily, as monotherapy or with lithium or valproate. Shown effective from 20 to 120 mg per day. Maximum 120 mg per day.In practiceStart 20 mg with food, usually at dinner. Titrate as needed toward 20 to 80 mg per day. Reassess at 2 weeks; go to 40 mg if the response is partial.

Kidney or liver impairmentwhere the label gives a dose

Kidney, moderate or severeFDA labelDose adjustment recommended for CrCl 30 to <50 or <30 mL/min. Start 20 mg per day; should not exceed 80 mg per day.In practiceStart 20 mg per day; cap at 80 mg per day. Cap the dose at 50% of usual, including end-stage kidney disease.

Liver, moderateFDA labelModerate (Child-Pugh 7 to 9): dose adjustment recommended. Start 20 mg per day; should not exceed 80 mg per day.In practiceStart 20 mg per day. Cap the dose at 50% of usual, maximum 80 mg per day.

Liver, severeFDA labelSevere (Child-Pugh 10 to 15): dose adjustment recommended. Start 20 mg per day; should not exceed 40 mg per day.In practiceStart 20 mg per day; maximum 40 mg per day.

Children and teensFDA labelSchizophrenia 13–17: start 40 mg, maximum 80 mg per day. Bipolar depression 10–17: start 20 mg as monotherapy, maximum 80 mg per day.In practiceApproved ages 13 to 17 (schizophrenia) and 10 to 17 (bipolar depression). Bipolar start 20 mg; range 20 to 80 mg per day.

Older adultsFDA labelUnknown whether dose adjustment is needed for age alone.In practiceNo dose adjustment required for age alone. Watch for orthostatic hypotension with early titration.

When to take itFDA labelShould be taken with food, at least 350 calories.In practiceEvening with the main meal. If activated or insomniac (unusual; can happen at higher doses), morning with breakfast of at least 350 kcal.

StoppingFDA labelEffectiveness beyond 6 weeks is not established in controlled studies. Re-evaluate long-term use periodically.In practiceBipolar depression: continue 6 to 12 months after remission, then taper if stopping (1 to 2 months; a slow taper is optional).

Interacting drugsFDA labelStrong inhibitor or inducer: should not be used. Moderate inhibitor added to LATUDA: halve the dose. LATUDA added to one: start 20 mg, max 80 mg/day.In practiceStrong inhibitor or inducer: contraindicated. Moderate inhibitor: halve the dose if already on LATUDA, otherwise start 20 mg and cap at 80 mg per day.

IndicationsFull section

FDA-approved

Schizophrenia (adults; adolescents 13–17)

Bipolar I depression, monotherapy or with lithium/valproate

Pediatric bipolar depression, ages 10–17

Off-label, evidence-based

Adjunct for unipolar MDD (no dedicated RCTs)MDD with mixed featuresDepressed phase of schizoaffective disorder

Boxed warningsFull section

Dementia-related psychosis mortality in the elderlyRelative risk about 1.6 to 1.7; lowest dose, shortest time, informed consent

Suicidality in children, teens, young adultsMonitor for worsening, especially early and after dose changes, under about 25

ContraindicationsFull section

Strong CYP3A4 inhibitorsKetoconazole (~7× levels), clarithromycin, ritonavir, nefazodone; do not co-prescribe

Strong CYP3A4 inducersRifampin, carbamazepine, phenytoin, St. John's wort; levels fall ~85%

MonitorFull section

Akathisia, EPSAsk about motor restlessness at every early visit

Weight/BMIBaseline, 2–4 wk, 3–4 mo, then annually

Glucose/A1c, lipidsBaseline, ~3–4 mo, then annually; every ~6 mo if drifting

BP, orthostaticsBaseline and early in treatment

AIMSBaseline, then every 6–12 mo

CYP3A4 med listAt start and whenever a new drug is added

No serum level, no routine ECG (QT ~1.5 ms) and no routine prolactin.

Drug interactionsFull section

Drug-drug

Strong CYP3A4 inhibitorsKetoconazole, itraconazole, voriconazole, clarithromycin, ritonavir: levels up ~7-fold; contraindicated

Strong CYP3A4 inducersRifampin ~85% reduction; carbamazepine is the sneaky one in bipolar; drug is effectively non-functional

Moderate CYP3A4 inhibitorsDiltiazem, verapamil, erythromycin, fluconazole: levels roughly double; start 20 mg, max 80 mg/day

Grapefruit, grapefruit juiceNot contraindicated, but the label says to avoid

Moderate CYP3A4 inducersBosentan, efavirenz, etravirine, modafinil, nafcillin: may need a dose increase, watch for lost efficacy

CYP enzymes

CYP3A4Substrate; the principal pathwayStrong inhibitors/inducers contraindicated; moderate inhibitors: max 80 mg/day

Must counselFull section

FoodTake it with a real meal, at least 350 calories; not a cracker or coffee

RestlessnessTrouble sitting still or a need to pace: tell me, a lower dose often fixes it

SleepinessCommon; take it with your evening meal

NauseaUsually early and settles; the meal helps

Dizziness on standingRise slowly and stay hydrated, especially early on

Grapefruit, St. John's wortAvoid both; tell me about any new medicine

Suicidal thoughtsCall right away if new or worse, especially under 25

PearlsFull section

The commonest cause of non-response is an empty stomach: ≥350 kcal with every dose, or absorption halves or worse.

No dose-response in bipolar depression (53% vs 51% response at low vs high dose). Higher doses add akathisia, not benefit.

Akathisia (~13% vs 3%) is the leading reason people quit. Lower the dose first, then propranolol 20–40 mg BID; benztropine does not treat it well.

Carbamazepine is the sneaky inducer: a bipolar patient may arrive on it, and it is contraindicated. Ask about grapefruit and St. John's wort too.

No antimanic or maintenance evidence: pair it with lithium or valproate when the patient needs mania protection, or choose another agent.

Summary of this guide. Check the full sections before prescribing.

Photo credits

Latuda (lurasidone) 40 mg bottle and tablets: Martyd215, CC BY-SA 4.0, Wikimedia Commons

Why Lurasidone Matters

Lurasidone has a specific and useful niche: it is the second-generation antipsychotic you reach for when metabolic safety matters and the target is bipolar depression rather than mania. It is one of a short list of agents FDA-approved for bipolar I depression, and of those it is arguably the most metabolically clean, with minimal weight gain, nearly flat lipids and glucose, negligible QT effect, and low prolactin. In a class defined by weight gain and dyslipidemia, that profile is its whole reason for existing.

The trade-offs are just as specific. Lurasidone has no antimanic evidence. It was never tested in acute mania and should not be used as bipolar monotherapy for a patient who cycles into mania without mood-stabilizer coverage. Its akathisia burden is real, and it is the leading tolerability reason people stop the drug. It also has an absorption quirk: it should be taken with a meal of at least 350 calories, or the patient absorbs roughly half the dose or less. Ziprasidone also has to be taken with food; lurasidone is the one whose label sets a specific calorie floor. More than a few "non-responders" are simply people who took their tablet on an empty stomach.

It is now generic, roughly $10 to $20 a month, down from about $1,000 a month at launch, so the cost barrier that once kept it in prior-authorization limbo is gone. That counts in its favor too.

Part 1: Indications

FDA-Approved Uses

• Schizophrenia (adults, 2010; adolescents 13 to 17, later extension)
• Bipolar I depression (2013), both as monotherapy and as adjunct to lithium or valproate (pediatric bipolar depression, ages 10 to 17, subsequently approved)

There is no indication for acute mania and no maintenance/prophylaxis indication; a brief bipolar maintenance trial did not succeed at 6 months. Lurasidone is a depression-and-psychosis drug, not a mania drug.

The Evidence-Based Clinical Uses

Bipolar I depression: the sweet spot. A 6-week placebo-controlled monotherapy trial with two dose arms showed response around 51 to 53% vs about 30% placebo, with remission around 40 to 42% vs about 25%. As adjunct to lithium or valproate, response was about 57% vs 42% and remission about 50% vs 35%. The efficacy is solid, and it comes without the metabolic penalty of quetiapine or the olanzapine-fluoxetine combination.

Schizophrenia. Solidly effective: 4 of 5 placebo-controlled pivotal trials were positive, and a network meta-analysis of 10 RCTs confirmed that all doses except 20 mg beat placebo. Here, unlike in depression, efficacy is dose-dependent: 80 mg/day is roughly the "effective dose 50," and 160 mg/day outperforms all lower doses on PANSS. It is a mid-range-efficacy antipsychotic (not clozapine, not olanzapine for refractory positive symptoms), chosen largely for its tolerability rather than raw potency.

Bipolar depression with cognitive complaints. Lurasidone is the antipsychotic most often cited for a possible pro-cognitive signal, tied to its strong 5-HT7 antagonism. Be honest about the evidence: the human cognition data are modest, partly sponsor-driven, and in a head-to-head against ziprasidone showed no clear advantage. The "cognition" endpoint in the schizophrenia trial was a PANSS subscale (thought organization), not formal neuropsychological testing. Reasonable to prefer it when cognition is a stated concern; don't oversell it.

Off-label, defensible: adjunctive treatment of unipolar major depression has no dedicated RCTs. Still, lurasidone clearly works in bipolar depression, and several antipsychotics (aripiprazole, brexpiprazole, cariprazine, quetiapine) share a class antidepressant-augmentation effect (NNT about 4), so it is a logical, if not yet data-based, augmentation choice, particularly for patients who cannot tolerate aripiprazole or quetiapine. Also reasonable: major depression with mixed features, and the depressed phase of schizoaffective disorder.

Worst Uses

• Acute mania: never tested; no antimanic evidence. Do not treat mania with lurasidone.
• Bipolar I monotherapy in a patient who needs mania protection: pair it with lithium/valproate, or choose a different agent.
• Bipolar maintenance monotherapy: the preventive data are not there yet.

Part 2: Before You Start: Workup and Candidacy

Lurasidone's baseline workup is the standard second-generation-antipsychotic metabolic panel, lighter than lithium's, because there is no narrow therapeutic window and no serum level to chase.

Baseline Assessment

Who Is a Poor Candidate?

• Anyone on a strong CYP3A4 inhibitor or inducer (see Part 7): these are contraindications, not cautions
• Patients who cannot or will not reliably eat with the dose: the food requirement is non-negotiable for absorption
• Patients whose target syndrome is mania or who need maintenance mood stabilization without added coverage
• History of severe, treatment-limiting akathisia on prior high-akathisia agents (aripiprazole, ziprasidone): relative caution
• Moderate to severe renal or hepatic impairment: usable, but cap the dose (Part 8)

Part 3: How to Start and Dose

Formulations

• Oral tablets only: 20, 40, 60, 80, 120 mg (the 60 mg was added post-launch)
• No IM, no long-acting injectable, no sublingual. It is a once-daily oral drug and nothing else.

The Food Rule

This is the most important sentence in this guide: Lurasidone should be taken with food of at least 350 calories. Fasting reduces absorption dramatically, since food roughly doubles to triples serum concentration. The composition matters less than the caloric floor; about 350 kcal is the validated threshold. The dose does not need to be taken at dinner specifically, but it should be taken with a substantial meal or snack.

Timing

Because sedation is common, evening dosing with the evening meal is the default: it converts a side effect (somnolence) into a benefit (sleep) and reliably pairs the dose with a real meal. If a patient is activated or insomniac on it, which is unusual for this drug but can happen at higher doses, morning dosing with breakfast is the alternative, again only if that breakfast is at least 350 kcal.

There is no serum level to monitor and no titration to a blood target. Dose to clinical response and tolerability.

Stopping and Switching

• Discontinuation: taper to reduce the risk of relapse; its low metabolic burden makes lurasidone a common switch target from more metabolically active atypicals.

Part 4: Monitoring

Monitoring lurasidone means watching the metabolic panel and looking for movement disorders. Unlike lithium, there are no levels to chase. The label sets no intervals for these checks (it asks for clinical weight monitoring, and fasting glucose at the start and periodically in patients with diabetes or risk factors); the schedule below is usual practice.

Movement disorders: perform an AIMS at baseline, then at least every 6 to 12 months (every 6 months is prudent in higher-risk patients). Ask about restlessness/inner tension at every early visit: akathisia is frequently missed because patients describe it as anxiety or agitation, and it is the leading tolerability reason people quit lurasidone.

Prolactin: routine measurement is not required. Increases are small (about 2 to 7 ng/mL, dose-related) and usually not clinically meaningful; check only if symptomatic (galactorrhea, menstrual change, sexual dysfunction).

ECG: not routine. Lurasidone's QT effect is negligible (mean about 1.5 ms; no patient with more than a 50 ms increase in trials, vs about 10 ms for ziprasidone). Obtain one only for cardiac history, QT-prolonging co-medications, or dosing above the approved range.

Part 5: Side Effects and How to Manage Them

As with the rest of the class, lurasidone's side effects are mostly dose-dependent, mostly early, and mostly manageable. Akathisia is the one that ends treatment, so pursue it actively rather than waiting for the patient to volunteer it.

Akathisia and EPS: the defining tolerability issue

This is lurasidone's Achilles' heel. From pooled trials: akathisia about 13% (vs 3% placebo); other EPS about 14% (vs 6%). It is dose-dependent and rises sharply above 40 mg. Reassuringly, dystonia (about 3%) and parkinsonism (about 4%) are lower than with risperidone.

Management, in order:

1. Lower the dose: often the cleanest fix, and for bipolar depression you lose no efficacy doing it.
2. Slow the titration if you were climbing.
3. Propranolol 20 to 40 mg BID to TID: the usual first pharmacologic choice in practice (the label gives no akathisia treatment); usually more effective than anticholinergics.
4. Benzodiazepine (lorazepam 0.5 to 1 mg or clonazepam 0.5 mg) as adjunct/PRN.
5. For parkinsonism/dystonia specifically, an anticholinergic (benztropine) is appropriate; note it does not treat akathisia well.

Sedation / Somnolence

Common: about 17% vs 7% placebo, dose-dependent (about 6% at 20 mg rising to about 22% at 120 mg). It occurs despite negligible antihistamine activity and is likely 5-HT7-mediated. More sedating than aripiprazole, less than quetiapine.

Management: dose in the evening; usually tolerable and often useful for the sleep-disrupted depressed patient. Lower the dose if daytime sedation persists.

Nausea / GI

About 10% vs 5% placebo, typically early. Conveniently, the mandatory food rule already mitigates it: taking the dose with a full meal reduces nausea. Ginger or a short course of an antiemetic covers the rest; nausea usually settles within days to a couple of weeks.

Insomnia / Activation

About 10% vs 8% placebo, more prominent at higher doses (120 to 160 mg), where anxiety, agitation, and fatigue also cluster. If activation appears, it usually means you've climbed too high: come back down.

Orthostatic Hypotension / Dizziness

From alpha-1 antagonism; usually early and mild. It was uncommon in the trials: orthostatic hypotension was reported in about 0.3% on lurasidone against 0.1% on placebo.

Management: rise slowly, hydrate, check standing BP early in treatment; slow titration and evening dosing help. Rarely dose-limiting.

Metabolic: the reason to choose this drug

This is lurasidone's main advantage:

• Weight: minimal, about half the incidence of clinically significant gain vs risperidone (about 7% vs about 14%); a 1-year open-label study showed a mean loss of about 3 lbs. A modest weight-gain signal appears above 40 mg.
• Lipids: no significant increase vs placebo.
• Glucose/HbA1c: nonsignificant changes.

Still, monitor: favorable is not immune, and individual patients gain.

Management of weight gain (when it occurs):

1. Early dietary counseling (simple, concrete: roughly a quarter less on the plate).
2. Metformin (e.g., 500 mg BID, titrated) for antipsychotic-associated gain.
3. Fish oil, about 4 g/day if triglycerides climb above 150.
4. Home weight self-monitoring to catch trends early.

Prolactin / Sexual

Small, usually subclinical prolactin rises; sexual dysfunction is less prominent than with risperidone/paliperidone. Manage symptomatically if it appears.

Class Effects to Keep in View

• Tardive dyskinesia: a class risk of any dopamine blocker, though second-generation agents carry roughly half the TD risk of typicals (annualized incidence about 2.6% against 6.5% across head-to-head trials; Carbon 2018, with an earlier pooled analysis, Correll and Schenk 2008, reporting 3.9% against 5.5%). AIMS surveillance is how you catch it early. Lurasidone's own EPS burden is real, but TD is a long-term, cumulative risk: watch for it over years.
• Neuroleptic malignant syndrome: rare but life-threatening (see Part 6).

Part 6: Toxicity and Boxed Warnings

Lurasidone has no narrow therapeutic window and no level-driven toxicity syndrome. The safety concerns are the class boxed warnings plus NMS.

Neuroleptic Malignant Syndrome (NMS)

Rare but potentially fatal: fever, rigidity, altered mental status, autonomic instability (labile BP, tachycardia, diaphoresis), often with elevated CPK.

Management: stop the antipsychotic immediately; supportive care (cooling, hydration, monitoring); dantrolene and/or bromocriptine in severe cases. This is an emergency.

Overdose

There is no specific antidote. Lurasidone overdose is generally managed supportively: airway/cardiac monitoring, symptomatic treatment (anticonvulsant for seizure, cooling for hyperthermia). Its clean QT and metabolic profile make isolated overdose comparatively less dangerous than some older agents, but co-ingestants and CYP3A4-mediated level elevations complicate the picture. Treat in an emergency setting.

Other Class Cautions

• Seizure threshold: dopamine blockade modestly lowers it; caution with seizure history.
• Metabolic emergencies (DKA, severe hyperglycemia): a class concern, though low-probability with lurasidone's flat glucose profile.

Part 7: Drug Interactions

Lurasidone is metabolized principally by CYP3A4, and its levels swing dramatically with 3A4 inhibitors and inducers. Have this interaction profile memorized before you prescribe, because the extremes are outright contraindications.

Part 8: Special Populations

Pregnancy

Lurasidone is a second-generation antipsychotic; human pregnancy data are limited (the pre-2015 label carried "Category B", a grade that reflected the absence of an animal teratogenicity signal rather than any human safety data). The general principles for antipsychotics in pregnancy apply:

• Untreated maternal illness carries its own substantial risk: relapse of bipolar depression or psychosis in pregnancy is dangerous to mother and fetus. Continuing an effective, well-tolerated agent is often the right call.
• Third-trimester exposure to antipsychotics carries a class-label warning for neonatal extrapyramidal symptoms and/or withdrawal (agitation, feeding difficulty, respiratory distress, hyper- or hypotonia, tremor), usually self-limited. Coordinate delivery planning and neonatal monitoring.
• Lurasidone's metabolic neutrality is a relative advantage over olanzapine/quetiapine (no added gestational-diabetes/weight burden).

Individualize; involve the patient in a documented risk-benefit discussion and coordinate with obstetrics. Consider enrollment in the National Pregnancy Registry for Psychiatric Medications.

Lactation

Lurasidone breast-milk data are minimal. Most atypicals appear in breast milk in small amounts; olanzapine, quetiapine, and risperidone have more reassuring lactation records. If a mother chooses to breastfeed on lurasidone, monitor the infant for sedation, poor feeding, and irritability, in coordination with pediatrics.

Elderly

• Age alone: the label says it is unknown whether dose adjustment is necessary on the basis of age alone; concentrations at 20 mg/day in patients 65 to 85 with psychosis were similar to those in young subjects. In practice, the dose is not adjusted for age alone.
• But watch orthostatic hypotension (fall risk) with early titration, and honor the dementia-related-psychosis boxed warning: lurasidone is not for that indication.

Renal Impairment

• Mild: no adjustment.
• Moderate to severe (and ESRD): cap the dose at 50% of usual, starting dose 20 mg, maximum 80 mg/day.

Hepatic Impairment

• Mild: no adjustment.
• Moderate (Child-Pugh 7 to 9): cap the dose at 50%, starting dose 20 mg, maximum 80 mg/day.
• Severe (Child-Pugh 10 to 15): starting dose 20 mg, maximum 40 mg/day.

Children and Adolescents

• Schizophrenia: approved ages 13 to 17.
• Bipolar depression: approved ages 10 to 17.
• Efficacy and the favorable metabolic profile carry over; akathisia and the food requirement remain the practical hurdles. Honor the pediatric suicidality monitoring warning.

Part 9: Discontinuation

Lurasidone has no distinctive withdrawal syndrome and no rebound analogous to lithium's. The concern on stopping is straightforward: relapse of the underlying illness, and, as with any dopamine blocker, the theoretical possibility of withdrawal dyskinesia with very abrupt cessation.

Practical approach:

• Bipolar depression: continue 6 to 12 months after remission, then taper if discontinuing.
• Taper over about 1 to 2 months rather than stopping cold: it's smoother, and it lets you catch early relapse.
• Schizophrenia: discontinuation decisions follow standard antipsychotic-maintenance logic (many patients need indefinite treatment); abrupt cessation risks psychotic relapse.
• Monitor for symptom re-emergence throughout and have a plan to resume promptly.

Part 10: Lurasidone vs the Alternatives

Where lurasidone best fits: the metabolically vulnerable patient with bipolar depression (or schizophrenia) for whom weight, lipids, glucose, QT, and prolactin all need to stay quiet, and who can reliably take it with a real meal.

Where it doesn't: mania, maintenance monotherapy, patients on strong 3A4 inhibitors/inducers, and patients who won't or can't eat with the dose.

Mechanism

Lurasidone is a D2 and 5-HT2A antagonist (the standard second-generation backbone: D2 blockade for antipsychotic effect, 5-HT2A blockade to soften EPS), distinguished by four features:

• Potent 5-HT7 antagonism: its most distinctive action, and the leading candidate mechanism for its antidepressant effect and any pro-cognitive signal, and is implicated, paradoxically given minimal antihistamine activity, in its sedation.
• 5-HT1A partial agonism: a likely additional contributor to antidepressant action, a mechanism it shares in spirit with buspirone, vilazodone, and aripiprazole.
• Alpha-1 antagonism: explains the orthostatic hypotension and early dizziness.
• Negligible muscarinic (M1) and histamine (H1) activity: the reason it is metabolically clean, with no antihistaminic weight/sedation-by-H1 mechanism and no anticholinergic burden (dry mouth, constipation, cognitive fog).

In depression, the serotonergic actions (5-HT7 and 5-HT2A antagonism, 5-HT1A partial agonism) are thought to carry the antidepressant benefit, while D2 blockade is more a liability at higher doses (emotional blunting, cognitive slowing), which is why the effective antidepressant dose sits low and pushing higher adds no benefit.

Pharmacokinetics: once-daily dosing; elimination half-life on the order of about 18 hours (with an active metabolite extending the net effect); metabolized primarily by CYP3A4; absorption doubled to tripled by food (label: take with at least 350 kcal).

The Bedside Cheat Sheet